Samsara Q2 FY27: ARR Tops $2.1B, Growth Holds at 30%, Defying Deceleration Fears

What happened

Samsara reported Q2 FY2027 results with annual recurring revenue (ARR) surpassing $2.1 billion, representing 30% year-over-year growth for the third consecutive quarter. This performance sharply exceeds the company's prior fiscal year 2027 revenue guidance of $1.965–1.975 billion (21–22% growth) provided just six months ago, signaling a significant upside surprise. The continued 30% growth rate contradicts earlier concerns about deceleration and suggests that enterprise momentum and emerging product traction remain robust. However, the press release snippet focuses solely on the top line, leaving key profitability, free cash flow, and margin details unverified, which are critical to assessing quality of growth. Investors should await the full shareholder letter and earnings call to confirm whether this growth is accompanied by sustained operating leverage and cash generation, or if it came with elevated costs.

Implication

The Q2 FY27 result materially de-risks the bear case that Samsara's growth would decelerate to the low-20s, as the 30% ARR growth strongly suggests the company is on track to exceed its initial FY27 revenue guidance. This should prompt management to raise full-year revenue expectations above $2.0 billion, a key catalyst previously identified in the master report for upgrading the investment thesis. However, the true test now shifts to profitability and free cash flow: if these metrics fail to expand in line with revenue, the market may punish the stock for quality-of-earnings concerns, especially given the large stock-based compensation and full valuation allowance. At the current valuation (implied by the master report's scenarios), much of the good news is likely already priced in; the risk/reward is less favorable after a potential post-earnings pop. Investors should closely monitor the next quarter for evidence that the 30% growth is sustainable without sacrificing margins, and watch for insider selling activity that could signal management's own assessment of valuation.

Thesis delta

The Q2 FY27 ARR print shifts the probability weight away from the bear case of growth decelerating to ~21% and toward the bull case of sustained high-20s growth. This effectively forces a guide raise at the next earnings update, which was the trigger for a more constructive stance. However, until we see margin and free cash flow follow-through, the valuation still leaves limited margin of safety, so the overall thesis remains WAIT but with an upward bias.